Related Experiment Video
Updated: Jun 6, 2026
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
[Malignant peritoneal mesothelioma: a case report]
1Oncologue, CH. Peltzer La Tourelle, Velviers, Belgique. hassan_kalantari@hotmail.com
Revue Medicale De Liege
|November 20, 2010
Summary
Malignant peritoneal mesothelioma, a rare cancer, presents challenges in diagnosis and treatment. Despite poor prognosis, early consideration in ascites cases is crucial for patient management.
Area of Science:
- Oncology
- Pathology
Background:
- Malignant mesothelioma primarily affects the pleura, with infra-diaphragmatic peritoneal mesothelioma accounting for only 10-20% of cases.
- Pathogenesis is often linked to asbestos and radiation exposure, though idiopathic cases exist.
Observation:
- Two cases of malignant peritoneal mesothelioma are presented, with one patient lacking a history of known exposures.
- Diagnosis was confirmed via laparoscopic biopsy and ascites fluid cytology.
- The condition predominantly affects males over 40 and is often diagnosed at advanced stages.
Findings:
- Malignant peritoneal mesothelioma has a significantly poorer prognosis (mean survival 5.4 months) compared to pleural mesothelioma (12.5 months).
- Treatment for localized disease may involve cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
- Advanced stages typically require palliative chemotherapy or radiotherapy for symptom management.
Implications:
- Peritoneal mesothelioma should be included in the differential diagnosis for unexplained ascites.
- Further research into the pathogenesis and treatment of this rare malignancy is warranted.
- Improved diagnostic strategies and earlier detection could potentially improve patient outcomes.
